e-learning
resources
Munich 2014
Monday, 08.09.2014
New technologies and biomarkers in lung disease
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
LATE-BREAKING ABSTRACT: Decreased sirtuin expression in squamous cell carcinoma compared to adenocarcinoma
D. Isajeva, S. Isajevs, G. Strazda, I. Silins, I. Taivans (Riga)
Source:
International Congress 2014 – New technologies and biomarkers in lung disease
Session:
New technologies and biomarkers in lung disease
Session type:
Poster Discussion
Number:
1813
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Isajeva, S. Isajevs, G. Strazda, I. Silins, I. Taivans (Riga). LATE-BREAKING ABSTRACT: Decreased sirtuin expression in squamous cell carcinoma compared to adenocarcinoma. Eur Respir J 2014; 44: Suppl. 58, 1813
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: What’s NEW in the 2022 ERS/ATS PFT Interpretation Statement
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
Differences in expression and prognostic values of p16(ink) and VEGF in squamous and adenocarcinoma of the lung
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014
Simultaneous EGFR and VEGF alterations in non-small cell lung carcinoma based on tissue microarrays
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014
A requirement for IKKa in lung adenocarcinoma
Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers
Year: 2015
Second primary lung cancer in squamous NSCLC patients: The Nancy Biobank's database
Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours
Year: 2014
Significance of EGFR expression patterns in patients with non-small cell lung cancer – Evaluation on protein- and/or gene level?
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014
LATE-BREAKING ABSTRACT: Prognostic value of microRNAs expression in stage I-IIIA lung adenocarcinoma (AC)
Source: Annual Congress 2013 –New strategies in epigenomic research to study lung diseases (DNA rearrangements, RNA, methylation, proteosome)
Year: 2013
The value of miR221 and miR222 as a biomarker in non small cell lung cancer
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014
Clinical significance of erythropoietin (Epo) and its receptor (EpoR) in non-small cell lung carcinoma
Source: International Congress 2014 – Biology and pathology of thoracic tumours
Year: 2014
Biological role of prognostic microRNAs (miRNAs) in squamous lung carcinoma (SCC) cells
Source: International Congress 2015 – Latest news on miRNAs in pulmonary research
Year: 2015
Methilation status in EBUS-NA samples of lung cancer
Source: International Congress 2014 – Improving diagnosis of thoracic tumours
Year: 2014
Molecular profiling of lung squamous carcinogenesis
Source: Annual Congress 2013 –Biology and molecular pathology of lung cancer
Year: 2013
CD33
+
CD14
-
CD11b
+
CD66b
+
CD15
+
VEGFR-1
hi
myeloid derived suppressor cells and their clinical relevance in non-small cell lung cancer
Source: International Congress 2014 – Biology and pathology of thoracic tumours
Year: 2014
Expression analysis of miR-21 in Bulgarian patients with non-small cell lung cancer
Source: International Congress 2016 – Prognostic variables in lung cancer I
Year: 2016
Frequency and type of EGFR mutations in patients with adenocarcinoma of the lung
Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Year: 2013
Safety and efficacy of erlotinib in patients with squamous cell lung cancer
Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series
Year: 2014
beta-F1-ATPase expression as a prognostic factor for resected non-small cell lung cancer
Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Year: 2013
Immunohistochemical expression of nuclear factor kappa-B/p65 and cyclooxygenase-2 in non-small cell lung cancer patients: Prognostic value and impact on survival
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014
Symptom-to-treatment intervals in lung cancer
Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series
Year: 2014
Role of hypoxia in epithelial-to-mesenchymal transition (EMT) in non-small cell lung cancer (NSCLC)
Source: International Congress 2014 – Basic and translational research in lung cancer and non-neoplastic pulmonary diseases
Year: 2014
Polymorphism of
HLA-G
gene promotor in patients with non small cell lung cancer
Source: International Congress 2014 – Biology and pathology of thoracic tumours
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept